Corporate Banner
Satellite Banner
Biologics & Bioprocessing
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Penn Pharma Invests £3million in Additional Manufacturing Capacity

Published: Thursday, July 18, 2013
Last Updated: Thursday, July 18, 2013
Bookmark and Share
Penn Pharma has announced its latest plans to invest in additional specific tablet manufacturing and coating capacity to meet customer demand.

This investment is in addition to the £14 million recently invested in a solid dose contained manufacturing facility to handle potent active pharmaceutical ingredients.

Penn Pharma Chief Executive Officer, Richard Yarwood, commented: “We are making this additional significant investment to meet our growing customer demands. It is fuelled by our demonstrated ability to provide pragmatic and timely solutions for their needs.  At a time when many businesses are struggling we are continuing to grow the Penn business and our recent investments give us the platform to provide even better services to our customers”.

The new £3million investment follows the recent completion of Penn Pharma’s new 15,000 sq ft site for the clinical and commercial manufacture of tablets and capsules. The new industry-leading facility will deliver both the clinical and commercial contained manufacturing needs of its clients.

Penn Pharma Chief Operating Officer, Mark Dean-Netscher, also commented: “Again, we at Penn are demonstrating our commitment to our customers and our growth as a business.  This additional investment will ensure we deliver to our customers and exceed expectations”.

Penn Pharma has been providing pharmaceutical services for over 30 years and employs 275 staff on its two sites in South Wales.  It has twice won the prestigious Queen’s Award for Enterprise in recognition of the work it provides to Export markets including the USA and Japan.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,300+ scientific posters on ePosters
  • More than 4,900+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

First Batch of Coated Tablets at New Penn Facility
International pharmaceutical manufacturer Penn Pharma has successfully completed the first batch of coated tablets in its new contained manufacturing operation.
Wednesday, May 08, 2013
Scientific News
Shedding Light on HIV Vaccine Design
Broadly speaking - Mathematical modelling of host-pathogen coevolution sheds light on HIV vaccine design.
Progress In Vaccination Against Vespid Venom
Researchers at the Helmholtz Zentrum München and the Technical University Munich have presented a method which facilitates a personalised procedure for wasp allergy sufferers.
FINCH Filgotinib Phase 3 Program Initiated
Galapagos NV reports the initiation of the FINCH global Phase 3 program in rheumatoid arthritis patient populations.
New Method of Cancer Immunotherapy
Stanford chemists have dicovered a new form of cancer immunotherapy using sugar presence manipulation.
Vortex Ring Freezing Applications
Accidental lab discovery could aid cell delivery and cell-free protein production.
Examining Immune Memory
Researchers investigate the 'storage/research for the future' functions of antibodies and understanding of B cells.
Expanding the Stable of Workhorse Yeasts
New genome sequences target the next generation of yeasts with improved biotechnology uses.
How Cloud Connectivity Can Combat the Reproducibility Crisis
This infographic explains the reproducibility crisis, and how cloud connectivity can help overcome this problem.
Blocking the Migration of Cancer Cells to Destroy Them
Scientists in Geneva developed an antibody able to fight off lymphomas.
Mutations Linked to Immunotherapy Resistance
Researchers uncover mutations in tumors of three patients with advanced melanoma that allowed the tumors to become resistant to the immune checkpoint inhibitor pembrolizumab (Keytruda®).
Skyscraper Banner

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,300+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,900+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!